Vectura partner launches Breelib nebuliser in Poland
First launch of product using FOX smart nebuliser.
Vectura's partner Bayer has launched Breelib, the new nebuliser for Ventavis (iloprost), in Poland. Breelib has been developed by Bayer in collaboration with Vectura, adapting Vectura's FOX handheld smart nebuliser device and utilising its unique flow rate and volume control technology. The launch triggers a €5 million milestone for the Group. Although the future financial value of this programme for the Group will be limited given the small patient population, this launch is an important validation of the FOX technology and its future potential. Vectura is eligible to receive annual milestones on the anniversary of this first launch on a decreasing scale, over six years, to the total value of €5.75 million.
The application of Ventavis with the Breelib nebuliser was approved by the European Medicines Agency in October 2016. Following the EC Declaration of Conformity, marketability of the medical device was granted by the EU Notified Body in December 2016.
The new Breelib device developed through this collaboration (VR876) with Bayer in the EU and Rest of World territories, excluding the US, has been designed to deliver Ventavis at an optimal particle size and to allow for a breath-actuated nebulisation at a fixed volume and flow rate, utilising the FOX®'s unique flow rate and volume control technology and thereby improving delivery to the lungs. In a clinical trial that compared Breelib with a currently recommended nebuliser, the new device demonstrated a reduction in mean inhalation time of each inhalation from approximately 11 minutes to approximately 3 minutes, providing for a significant reduction in the overall daily treatment duration for patients. These clinical trial results will be published in due course.
James Ward-Lilley, CEO of Vectura, said: "We are pleased to have supported Bayer in this collaboration enhancing drug delivery and ease of device usage for patients with pulmonary arterial hypertension. The launch of the Breelib device marks an important validation of Vectura's mesh based handheld device technology using the FOX smart nebuliser. Breelib's proprietary flow-rate and volume control system is also utilised in Vectura's jet based AKITA nebuliser platforms. Vectura expects to increase the utilisation of the mesh based nebuliser platforms with a number of further partnering collaborations."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance